Mitiglinide is a Small Molecule owned by Kissei Pharmaceutical, and is involved in 10 clinical trials, which were completed.
Mitiglinide is thought to stimulate insulin secretion by binding to and blocking ATP-sensitive potassium channels in pancreatic beta-cells. The closure of potassium channels causes depolarization which stimulates calcium influx through voltage-gated calcium channels. High intracellular calcium subsequently triggers the exocytosis of insulin granules.
The revenue for Mitiglinide is expected to reach a total of $42m through 2031. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Mitiglinide NPV Report.
Mitiglinide is originated and owned by Kissei Pharmaceutical.
Mitiglinide Overview
Mitiglinide calcium (Glufast) is a phenylpropanoic acid derivative, acts as an insulin secretagogue or anti-diabetic agent. It is formulated as tablets for oral route of administration. Glufast is indicated for treatment of type 2 diabetes and for post prandial glycemic control in type 2 diabetes mellitus.
It was under development for type 2 diabetes mellitus in Vietnam (ASEAN country)
Kissei Pharmaceutical Overview
Kissei Pharmaceutical (Kissei) discovers, develops, manufactures, and sells a range of innovative pharmaceutical products. The company’s pharmaceutical products include urological medicine, metabolic endocrinology medicine, drugs for kidney and dialysis department, drugs for obstetrics and gynecology, ophthalmic medicine and rare disease medicine. It also develops and sells health foods including protein-controlled food, energy supply food, calorie-controlled food, and elderly controlled food. Kissei conducts research to develop novel drugs and improve existing drugs and provide superior drugs to people worldwide. The company has sales offices across Japan and an overseas subsidiary in New Jersey, the US. Kissei is headquartered in Matsumoto, Japan.
The company reported revenues of (Yen) JPY65,381 million for the fiscal year ended March 2022 (FY2022), a decrease of 5.3% over FY2021. The operating loss of the company was JPY1,842 million in FY2022, compared to an operating profit of JPY2,151 million in FY2021. In FY2022, the company recorded a net margin of 19.8%, compared to a net margin of 7.7% in FY2021.
The company reported revenues of JPY16,579 million for the second quarter ended September 2022, an increase of 1.8% over the previous quarter.
Quick View – Mitiglinide
Report Segments |
|
Drug Name |
|
Administration Pathway |
|
Therapeutic Areas |
|
Key Companies |
|
Highest Development Stage |
|